<DOC>
	<DOCNO>NCT02860039</DOCNO>
	<brief_summary>This phase II randomize trial study well high dose flu vaccine work treat child undergone do stem cell transplant . Higher dose flu vaccine may build good immune response may provide good protection flu standard vaccine .</brief_summary>
	<brief_title>High Dose Flu Vaccine Treating Children Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether high-dose trivalent inactivate influenza vaccine ( HD-TIV ) compare standard dose quadrivalent inactivate influenza vaccine ( QIV ) increase probability achieve &gt; = 4-fold rise hemagglutination-inhibition ( HAI ) titer , &gt; = 1:40 HAI titer , high geometric mean titer ( GMT ) influenza A antigen pediatric hematopoietic stem cell transplant ( HSCT ) recipient . SECONDARY OBJECTIVES : I . To determine whether HD-TIV compare standard dose QIV increase probability achieve &gt; = 4-fold rise HAI titer , &gt; = 1:40 HAI titer , high GMT titer influenza B antigen pediatric HSCT recipient . II . To determine frequency severity solicit local injection site adverse event ( e.g . pain/ tenderness , redness , swell injection site ) HD-TIV compare standard QIV pediatric HSCT recipient . III . To determine frequency severity solicit systemic adverse event ( e.g . fever , headache , fatigue/malaise , nausea , body ache/myalgia , general activity level , vomit ) HD-TIV compare standard dose QIV pediatric HSCT recipient . IV . To define relationship HAI titer , vivo T B cell phenotype , vitro influenza-specific T B cell response pediatric HSCT recipient receive either HD-TIV standard dose QIV . V. To correlate HAI response microneutralization response . VI . To compare persistent HAI microneutralization ( MN ) titer four antigen seven month last vaccine dose assess persistence antibody titer . VII . To compare influenza detection PCR influenza season pediatric HSCT recipient receive either HD-TIV standard dose QIV . OUTLINE : Patients randomize 1 2 treatment group . GROUP I ( Experimental ) : Patients receive HD-TIV intramuscularly ( IM ) day 0 day 28 . GROUP II ( Standard ) : Patients receive standard dose QIV IM day 0 day 28 . After completion study treatment , patient follow 28-42 day , 7 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Allogeneic HSCT recipients 335 month posttransplant Available duration study If patient immunosuppressive therapy treatment graft versus host disease ( GVHD ) , stable dos least 4 week ( taper dos ) eligible Parent/legal guardian willing capable signing write informed consent Parent/legal guardian expect available entire study Parent/legal guardian reach telephone email Must platelet count ≥30,000 receive immunization . Patients require platelet transfusion eligible enroll must platelet count ≥30,000 within 72 hour prior immunization . For subject &lt; 12 month posttransplant , platelet count ≥75,000 document without transfusion support within 14 day immunization , additional platelet count need repeat prior immunization . For subject 1235 month posttransplant , platelet count ≥75,000 document without transfusion support within 90 day immunization , additional platelet count need repeat prior immunization . History hypersensitivity previous influenza vaccination severe moderate hypersensitivity eggs/egg protein History GuillainBarre syndrome Evidence hematologic malignancy disease relapse posttransplant ( stable mixed chimerisms permit ) History receive 20162017 influenza vaccine Pregnant female History proven influenza disease September 1 , 2016 Nonallogeneic ( e.g . autologous ) syngeneic hematopoietic stem cell transplant ( SCT ) recipients Platelet count le 30,000 cells/uL History know active infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C History know latex hypersensitivity Subjects receive stem cell boost delay donor lymphocyte infusion within 90 day enrollment , include day enrollment Receipt intravenous immunoglobulin therapy ( IVIG ) &lt; 27 day prior vaccination C34 selection exvivo Tcell depletion , posttransplant cytoxan aploidentical transplant allowable .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>